SCHEMBL6993930

SCHEMBL6993930

CCOC(=O)c1c(N)sc2c1CCN(CC)C2

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.72
ALDH1A1 P00352 11/20 0.72
GAA P10253 9/20 0.72
HPGD P15428 9/20 0.72
MEN1 O00255 7/20 0.72
KMT2A Q03164 7/20 0.72
KDM4E B2RXH2 7/20 0.72
ADORA1 P30542 5/20 0.72
LMNA P02545 1/20 0.72
POLB P06746 2/20 0.69
HSD17B10 Q99714 4/20 0.64
ALOX15 P16050 3/20 0.64
MAPK1 P28482 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.60
TSHR P16473 1/20 0.57
ALOX12 P18054 1/20 0.57
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
PTK2B Q14289 1/20 0.52
ESR2 Q92731 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6997277 0.90 ALDH1A1 (0.64) MAPTALDH1A1GAAHPGDMEN1
Oxalic Acid SCHEMBL10858717 0.88 MAPT (0.64) MAPTALDH1A1GAAHPGDMEN1
SCHEMBL17296424 0.87 MAPT (0.66) MAPTALDH1A1GAAHPGDMEN1
SCHEMBL22392278 0.87 GAA (0.69) MAPTALDH1A1GAAHPGDMEN1
SCHEMBL22392250 0.87 MAPT (0.66) MAPTALDH1A1GAAHPGDMEN1
SCHEMBL4504119 0.86 ALDH1A1 (0.67) MAPTALDH1A1GAAHPGDMEN1
SCHEMBL970355 0.85 ADORA1 (0.83) MAPTALDH1A1GAAHPGDMEN1
Tinoridine SCHEMBL24761 0.84 ADORA1 (1.00) MAPTALDH1A1GAAHPGDMEN1
SCHEMBL6993570 0.84 ADORA1 (0.84) MAPTALDH1A1GAAHPGDMEN1
SCHEMBL10862455 0.84 MAPT (0.80) MAPTALDH1A1GAAHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647725-B2 Anti-infective 2-aminothiophenes THE UNIVERSITY OF TOLEDO (US) 2020-05-12 US disclosed
US-20190119296-A1 Anti-Infective 2-Aminothiophenes THE UNIVERSITY OF TOLEDO (US) 2019-04-25 US disclosed
EP-3131890-B1 COMPOUNDS FOR TREATING VIRAL INFECTIONS PASTEUR INSTITUT KOREA (KR) 2019-04-24 EP disclosed
US-9902738-B2 Compounds and methods for preventing, treating and/or protecting against sensory hair cell death UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2018-02-27 US disclosed
US-9902738-B2 Compounds and methods for preventing, treating and/or protecting against sensory hair cell death UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2018-02-27 US disclosed
US-9809602-B2 Compounds for treating viral infections INSTITUT PASTEUR KOREA (KR) 2017-11-07 US disclosed
WO-2017184947-A1 ANTI-INFECTIVE 2-AMINOTHIOPHENES THE UNIVERSITY OF TOLEDO (US) 2017-10-26 WO disclosed
EP-2900674-B1 COMPOUNDS AND METHODS FOR PREVENTING, TREATING AND/OR PROTECTING AGAINST SENSORY HAIR CELL DEATH UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2017-05-31 EP disclosed
EP-2900674-B1 COMPOUNDS AND METHODS FOR PREVENTING, TREATING AND/OR PROTECTING AGAINST SENSORY HAIR CELL DEATH UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2017-05-31 EP disclosed
US-20170044181-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS INSTITUT PASTEUR KOREA (KR) 2017-02-16 US disclosed
US-9416141-B2 Compounds and methods for preventing, treating and/or protecting against sensory hair cell death UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) 2016-08-16 US disclosed
WO-2015158908-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS INSTITUT PASTEUR KOREA (KR) 2015-10-22 WO disclosed
US-20150232476-A1 COMPOUNDS AND METHODS FOR PREVENTING, TREATING AND/OR PROTECTING AGAINST SENSORY HAIR CELL DEATH UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION 2015-08-20 US disclosed
US-20150232476-A1 COMPOUNDS AND METHODS FOR PREVENTING, TREATING AND/OR PROTECTING AGAINST SENSORY HAIR CELL DEATH UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION 2015-08-20 US disclosed
EP-2900674-A1 COMPOUNDS AND METHODS FOR PREVENTING, TREATING AND/OR PROTECTING AGAINST SENSORY HAIR CELL DEATH University of Washington through its Center for Commercialization (US) 2015-08-05 EP disclosed
EP-0927184-B1 3-SUBSTITUTED PYRIDO 4',3':4,5]THIENO 2,3-D]PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE ABBOTT GMBH & CO KG (DE) 2003-10-22 EP disclosed
US-6387912-B1 STROKE THERAPY BASF AKTIENGESELLSCHAFT (DE) 2002-05-14 US disclosed
EP-1140096-A1 UTILIZATION OF PYRIMIDINE DERIVATIVES FOR PREVENTING AND TREATING CEREBRAL ISCHAEMIA BASF AKTIENGESELLSCHAFT (DE) 2001-10-10 EP disclosed
US-6222034-B1 AS SEROTININ RECEPTOR ANTAGONISTS; FOR THERAPY OF DEPRESSION, CENTRAL NERVOUS SYSTEM DISORDERS BASF AKTIENGESELLSCHAFT (DE) 2001-04-24 US disclosed
WO-2000041695-A1 UTILIZATION OF PYRIMIDINE DERIVATIVES FOR PREVENTING AND TREATING CEREBRAL ISCHAEMIA BASF AKTIENGESELLSCHAFT (DE) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119296-A1 Anti-Infective 2-Aminothiophenes TST, ABAT, TPMT MAPT 1615/4885ALDH1A1 2316/4885GAA 2551/4885
US-10647725-B2 Anti-infective 2-aminothiophenes TST, ABAT, TPMT MAPT 1615/4885ALDH1A1 2316/4885GAA 2551/4885
US-20170044181-A1 COMPOUNDS FOR TREATING VIRAL INFECTIONS HAVCR2, MAVS, EIF2AK2 MAPT 2197/4885ALDH1A1 676/4885GAA 77/4885
US-20150232476-A1 COMPOUNDS AND METHODS FOR PREVENTING, TREATING AND/OR PROTECTING AGAINST SENSORY HAIR CELL DEATH BAX, CASP3, BCL2 MAPT 2252/4885ALDH1A1 426/4885GAA 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.